Harpoon Therapeutics Inc(HARP) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The firm is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.

Current Price

$22.42

RSI

56.049

Beta:

0.810684

March 10, 2021
13.5M
-15.2M

235.363 %
114.194 %
19.533 %
17.988 %
$17,444,000
$5,777,000
201.956 %
$-49,946,000
$-55,572,000
11.264 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.